Management of Treatment-Experienced Patients

Faculty:

Joseph J. Eron, Jr., MD Kimberly Y. Smith, MD, MPH Andrew R. Zolopa, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Recount recent data from the DUET trials describing baseline characteristics predictive of etravirine response
• Discuss the results of a study assessing the virologic response in patients treated with the combination of raltegravir, darunavir/ritonavir, and etravirine
• Describe the associated affects of maraviroc on CD4+ cell count increases when compared with placebo
• Explain the virologic outcomes associated with a switch from enfuvirtide to raltegravir
• Identify investigational NNRTIs in early stages of clinical development

Topics covered include:

• Patient Characteristics Predictive of Etravirine Response Include Baseline Viral Load and CD4+ Cell Count but not Sex or Race
• Correlating Etravirine and Darunavir Resistance to Patient Response: Week 24 Subgroup Analysis of DUET Trials
• GRACE Interim Analysis: The Role of Patient Sex and Race in Response to Darunavir/Ritonavir
• Etravirine Safety: Lack of Associated Fetal and Neurologic Toxicity but Increased Incidence of Rash
• Preliminary Safety and Efficacy Report on US Patients in the Etravirine Early Access Program
• Switch From Enfuvirtide to Raltegravir With Virologic Suppression
• TRIO: Week 24 Efficacy of Regimens Containing the Combination of Raltegravir, Etravirine, and Darunavir/Ritonavir
• MOTIVATE Subanalyses: Immunologic Affects Associated With CCR5 Inhibition and Virologic Response by Baseline Viral Load
• Pharmacokinetics of the Heat-Stable Ritonavir Tablet Formulation
• Update on Investigational Antiretroviral Agents: Rilpivirine, RDEA806, and IDX899